Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Nurix Therapeutics (NRIX) Accumulated Depreciation & Amortization: 2019-2025

Historic Accumulated Depreciation & Amortization for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $40.7 million.

  • Nurix Therapeutics' Accumulated Depreciation & Amortization rose 26.88% to $40.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $150.7 million, marking a year-over-year increase of 67.25%. This contributed to the annual value of $9.3 million for FY2024, which is 23.70% up from last year.
  • According to the latest figures from Q3 2025, Nurix Therapeutics' Accumulated Depreciation & Amortization is $40.7 million, which was up 5.24% from $38.7 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $40.7 million in Q3 2025 and a low of $1.8 million during Q1 2023.
  • Over the past 3 years, Nurix Therapeutics' median Accumulated Depreciation & Amortization value was $29.7 million (recorded in 2024), while the average stood at $26.4 million.
  • In the last 5 years, Nurix Therapeutics' Accumulated Depreciation & Amortization plummeted by 88.85% in 2023 and then skyrocketed by 1,697.75% in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Accumulated Depreciation & Amortization stood at $14.9 million in 2021, then spiked by 32.20% to $19.7 million in 2022, then surged by 33.45% to $26.2 million in 2023, then soared by 31.44% to $34.5 million in 2024, then climbed by 26.88% to $40.7 million in 2025.
  • Its Accumulated Depreciation & Amortization was $40.7 million in Q3 2025, compared to $38.7 million in Q2 2025 and $36.8 million in Q1 2025.